On December 5, 2025 ImCheck Therapeutics reported an oral presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting 2025, taking place from December 6 to December 9, in Orlando, FL, USA. The presentation will highlight the high remission rates and overall survival observed in EVICTION, ImCheck’s open-label, randomized Phase I/II study evaluating ICT01, a first-in-class γ9δ2 T-cell activator, in combination with azacitidine and venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation at ASH (Free ASH Whitepaper) 2025 are:

Abstract Title: "γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction"

Presenter: Sylvain GARCIAZ, MD, PhD, Institut Paoli-Calmettes, Marseille, France

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML

Room: OCCC – Chapin Theater (320)

Date: Sunday, December 7, 2025

Time: 5:15 p.m.- 5:30 p.m. ET

The ASH (Free ASH Whitepaper) presentation will be available on ImCheck’s corporate website after the presentation has been held.

(Press release, ImCheck Therapeutics, DEC 5, 2025, View Source [SID1234661174])